Human xanthine oxidase recombinant in E. coli: A whole cell catalyst for preparative drug metabolite synthesis.

Human xanthine oxidoreductase (XOR), which is responsible for the final steps of the purine metabolism pathway and involved in oxidative drug metabolism, was successfully expressed in Escherichia coli BL21(DE3) Gold. Recombinant human (rh) XOR yielded higher productivity with the gene sequence optimized for expression in E.coli than with the native gene sequence. Induction of XOR expression with lactose or IPTG resulted in complete loss of activity whereas shake flasks cultures using media rather poor in nutrients resulted in functional XOR expression in the stationary phase. LB medium was used for a 25L fermentation in fed-batch mode, which led to a 5 fold increase of the enzyme productivity when compared to cultivation in shake flasks. Quinazoline was used as a substrate on the semi-preparative scale using an optimized whole cell biotransformation protocol, yielding 73mg of the isolated product, 4-quinazolinone, from 104mg of starting material.

[1]  K. Shanmugam,et al.  Global gene expression analysis revealed an unsuspected deo operon under the control of molybdate sensor, ModE protein, in Escherichia coli , 2005, Archives of Microbiology.

[2]  T. Ahn,et al.  High-level expression of human cytochrome P450 3A4 by co-expression with Human molecular chaperone HDJ-1 (Hsp40) , 2004, Archives of pharmacal research.

[3]  F. Bergmann,et al.  The Enzymatic Oxidation of 6-Mercaptopurine to 6-Thiouric Acid1 , 1960 .

[4]  K. Rajagopalan,et al.  Molybdenum cofactor biosynthesis in Escherichia coli. Requirement of the chlB gene product for the formation of molybdopterin guanine dinucleotide. , 1991, The Journal of biological chemistry.

[5]  Martina Geier,et al.  Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis , 2015, Microbial Cell Factories.

[6]  S. Leimkühler,et al.  Molybdenum enzymes, their maturation and molybdenum cofactor biosynthesis in Escherichia coli. , 2013, Biochimica et biophysica acta.

[7]  E. Garattini,et al.  Increasing recognition of the importance of aldehyde oxidase in drug development and discovery , 2011, Drug metabolism reviews.

[8]  Y. Moriwaki,et al.  In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver. , 1987, Biochemical pharmacology.

[9]  Imad Hanna,et al.  Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli , 2005, Journal of Industrial Microbiology and Biotechnology.

[10]  G. Gordon Gibson,et al.  Introduction to Drug Metabolism , 1986, Springer US.

[11]  A. C. Collins,et al.  Mouse brain ATPase activities after chronic nicotine infusion. , 1987, Biochemical Pharmacology.

[12]  F. Stirpe,et al.  The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. , 1972, The Biochemical journal.

[13]  Anton Glieder,et al.  Expression of recombinant human flavin monooxygenase and moclobemide-N-oxide synthesis on multi-mg scale. , 2012, Chemical communications.

[14]  K. Okamoto,et al.  Human xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate. , 2007, Journal of biochemistry.

[15]  J. McCormack,et al.  Oxidation of selected pteridine derivatives by mamalian liver xanthine oxidase and aldehyde oxidase. , 1976, Journal of pharmaceutical sciences.

[16]  D. Rees,et al.  Molybdenum-cofactor-containing enzymes: structure and mechanism. , 1997, Annual review of biochemistry.

[17]  R. Dempski,et al.  The Reductive Half-reaction of Xanthine Oxidase , 1999, The Journal of Biological Chemistry.

[18]  Leah Tolosa,et al.  Noninvasive measurement of dissolved oxygen in shake flasks. , 2002, Biotechnology and bioengineering.

[19]  C. Szabó,et al.  Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.

[20]  T. Ahn,et al.  Enhanced expression of human cytochrome P450 1A2 by co-expression with human molecular chaperone Hsp70. , 2004, Toxicology letters.

[21]  W. Hall,et al.  Xanthine oxidase from human liver: purification and characterization. , 1986, Archives of biochemistry and biophysics.

[22]  G. Giordano,et al.  Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis Protein MobA* , 2003, Journal of Biological Chemistry.

[23]  Anton Glieder,et al.  Production of Recombinant Human Aldehyde Oxidase in Escherichia coli and Optimization of Its Application for the Preparative Synthesis of Oxidized Drug Metabolites , 2014 .

[24]  Enrico Garattini,et al.  The role of aldehyde oxidase in drug metabolism , 2012, Expert opinion on drug metabolism & toxicology.

[25]  Matthias Kittelmann,et al.  Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis. , 2010, Biotechnology and Bioengineering.

[26]  W. Deckwer,et al.  High cell density cultivation of Escherichia coli at controlled specific growth rate. , 1991, Journal of biotechnology.

[27]  S. Kitamura,et al.  Drug-metabolizing ability of molybdenum hydroxylases. , 2006, Drug metabolism and pharmacokinetics.

[28]  M. Haumann,et al.  Identification of a Bis-molybdopterin Intermediate in Molybdenum Cofactor Biosynthesis in Escherichia coli* , 2013, The Journal of Biological Chemistry.

[29]  J. McCord,et al.  Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.

[30]  Michael D. Coleman,et al.  Human Drug Metabolism , 2020 .

[31]  S. Yee,et al.  Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. , 1997, Archives of biochemistry and biophysics.

[32]  P. de Miranda,et al.  6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Pritsos.  Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. , 2000, Chemico-biological interactions.

[34]  M. Romão,et al.  Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. , 2003, The Biochemical journal.